Lutikizumab
As of the edition of 20 October 2026, Lutikizumab is an antibody: in active development; acts on IL1A and IL1B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 12, 0 stopped early
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Immune system; Infections; Digestive system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 9 | 2 | 7 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AbbVie | Lead sponsor of trials | 2012 to now |